派罗欣联合胸腺肽对HBeAg阳性慢性乙肝患者的疗效观察

Observation of the curative effect of Pegasys combined with thymosin in patients with HBeAg positive chronic hepatitis B

目的:探讨派罗欣联合胸腺肽对HBeAg阳性慢性乙肝患者的疗效。方法:收治HBeAg阳性慢性乙肝患者96例,分两组,各48例,观察组予以派罗欣联合胸腺肽的治疗措施,对照组单独使用派罗欣的治疗措施,观察两组患者的临床治疗效果。结果:观察组HBeAg转阴率以及HBV-DNA转阴率均显著高于对照组(P<0.05);观察组治疗后的不良反应总发生率6.3%,显著低于对照组的20.8%(P<0.05)。结论:对HBeAg阳性慢性乙肝患者采用派罗欣联合胸腺肽的药物治疗措施达到了更高的转阴率,安全、可靠。

Objective:To discuss the curative effect of Pegasys combined with thymosin in patients with HBeAg positive chronic hepatitis B.Methods:96 patients with HBeAg positive chronic hepatitis B were selected.They were divided into two groups, 48 cases in each.Patients in the observation group of patients were treated with Pegasys combined with thymosin treatment,while patients in the control group were alone in patients with Pegasys treatmen.The clinical therapeutic effect of two groups was observed.Results:The HBeAg negative conversion rate and HBV-DNA negative rate of the observation group were significantly higher than those of the control group(P<0.05);adverse reactions rate of the observation group was 6.3%,which was significantly lower than that of the control group 20.8% (P<0.05).Conclusion:For HBeAg positive chronic hepatitis B patients,Pegasys combined with thymosin reached higher negative rate,safe and reliable.